Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence in Phase 3 Trial
Personalized therapy intismeran showed clinically meaningful improvement over standard immunotherapy, triggering a massive surge in Moderna's stock.
Moderna and Merck have announced that their personalized mRNA cancer vaccine, intismeran, successfully met its primary endpoint in a Phase 3 clinical trial. The results mark a pivotal shift for mRNA technology, moving it beyond the pandemic and into the forefront of individualized oncology.
In the INTerpath-001 trial, intismeran was administered in combination with the immunotherapy drug Keytruda to patients with high-risk melanoma. The combination therapy significantly reduced the risk of cancer recurrence and distant spread compared to patients receiving Keytruda monotherapy. Unlike traditional vaccines, intismeran is personalized to each patient, training the immune system to target up to 34 unique mutations found within an individual's specific tumor.
A Volatile Recovery
This breakthrough arrives during a period of extreme instability for Moderna. The company's market value previously plummeted by over 90% as global demand for COVID-19 vaccines evaporated. The announcement of the trial's success triggered an immediate market reaction, with Moderna's shares surging 177% on Wednesday, August 19, 2026.
The scientific victory also comes amid a challenging political climate. The Trump administration, via the Department of Health and Human Services and RFK Jr., recently cut nearly $500 million in federal funding for mRNA research through BARDA, asserting that the technology posed more risks than rewards.
The Shift to Individualized Oncology
For the industry, the success of intismeran validates the personalized mRNA platform as a transformational tool for cancer therapy. By proving that a vaccine can be tailored to a patient's unique tumor biology, the partnership has opened the door for similar applications in other difficult-to-treat malignancies, including kidney, bladder, and pancreatic cancers.
"People will experience this as ... the COVID company now [takes on] cancer," said Moderna President Stephen Hoge, describing the move as the company finally "coming home" to its original oncology goals. William Soliman, CEO of the Accreditation Council for Medical Affairs, noted that the medical community may be entering an era where therapy is designed specifically for a patient's individual tumor biology.
Next Steps
While the Phase 3 results provide a strong foundation for regulatory filing, the companies have not yet confirmed a specific date for commercial launch. Observers will now watch for the submission of formal applications to health regulators and the potential expansion of the personalized mRNA platform into other cancer types to see if the melanoma results can be replicated across the broader oncology landscape.